In addition, inactivation of GPX4 and subsequent induction of ferroptosis has been shown to selectively ablate drug tolerant cell populations in preclinical models of melanoma, as well as other cancer types, whilst having little effect on treatment naïve cell populations [71]. The gene discussed is GPX4; the disease is melanoma.